PolyPid (NASDAQ:PYPD) Raised to “Strong-Buy” at RODMAN&RENSHAW

RODMAN&RENSHAW upgraded shares of PolyPid (NASDAQ:PYPD) to a strong-buy rating in a research report released on Tuesday,Zacks.com reports.

A number of other equities research analysts have also recently weighed in on the company. Rodman & Renshaw initiated coverage on PolyPid in a report on Tuesday. They set a “buy” rating and a $13.00 price target on the stock. HC Wainwright reduced their price target on PolyPid from $14.00 to $11.00 and set a “buy” rating for the company in a research report on Thursday, December 26th. Finally, Craig Hallum began coverage on PolyPid in a research note on Monday, November 4th. They issued a “buy” rating and a $10.00 price target for the company.

PolyPid Stock Down 7.3 %

PolyPid stock opened at $2.92 on Tuesday. The firm has a market capitalization of $14.02 million, a P/E ratio of -0.37 and a beta of 1.32. The company has a 50-day simple moving average of $3.12 and a 200-day simple moving average of $3.37. PolyPid has a one year low of $2.37 and a one year high of $7.00. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.00 and a current ratio of 1.00.

Institutional Trading of PolyPid

A hedge fund recently raised its stake in PolyPid stock. Rosalind Advisors Inc. increased its position in shares of PolyPid Ltd. (NASDAQ:PYPD) by 62.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 679,168 shares of the company’s stock after acquiring an additional 262,368 shares during the period. PolyPid makes up about 1.5% of Rosalind Advisors Inc.’s investment portfolio, making the stock its 18th largest position. Rosalind Advisors Inc. owned approximately 14.16% of PolyPid worth $2,336,000 at the end of the most recent quarter. 26.47% of the stock is currently owned by institutional investors.

PolyPid Company Profile

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.